Skip to content
  • Facebook
  • Twitter
  • Instagram
  • Email
NEWSX 360 : The Global News Platform

NEWSX 360 : The Global News Platform

News from across the Globe

  • Home
  • About Us
  • Terms & Conditions
  • Contact Us
  • Editor’s Note
  • Privacy Policy
  • Toggle search form
  • “Is it for real?” Trains now serve Homemade Jain food and Regional Delicacies, Thanks to this App! News
  • 17 year old boy with complicated massive heart attack undergoes successful angioplasty stenting at SSB Hospital – Survives News
  • India’s first student Trishla gowani makes history by gracing the Cannes film festival 2023 News
  • AM/NS India’s fire team rescues dumper truck driver from mangled cabin after accident News
  • Rajkot’s Smart City Vision: Municipal Corporation’s Bold Steps with Bond Issue for Water and Sewerage Expansion News
  • Amitabh Bachchan lent his voice to the film “The Lipstick Boy”, Directed by Abhinav Thakur News
  • BITS Pilani hosts Waves 2023, sets new benchmark for cultural festivals in Goa News
  • Rudra Ecovation x AYCS: A Resounding Success in Promoting Sustainable Fashion News

Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.

Posted on May 28, 2022 By No Comments on Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.

Pharma Desk, India: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen). Ivabradine Tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Ivabradine Tablets are indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses. Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US$ 102 million for twelve months ending December 2021 according to IQVIA. Alembic has received a cumulative total of 164 ANDA approvals (140 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients. Information about Alembic can be found at https://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

Related

Uncategorized

Post navigation

Previous Post: Vadodara based female entrepreneur launches India’s first eco friendly products e commerce portal zeroite.com
Next Post: Comprehensive Men’s Sexual Health Solutions Added to Buenafe Clinic

Related Posts

  • Fungicides Market to Reach US$ 22.3 Bn by 2027, TMR Study Uncategorized
  • Sage Geosystems Announces Strategic Partnership and Investment from IGNIS H2 Energy and the Geolog Group to Advance Energy Storage Solutions Using Geothermal Technology Uncategorized
  • Expert opinion:5 D2C Retail Trends Shaping Consumer-Brand Relationship Uncategorized
  • Retort Packaging Demand to Grow 1.7% Annually Through 2026 Uncategorized
  • Los nuevos módulos Vertex N de Trina Solar redefinen los productos de alta eficiencia y la capacidad de más de 10 GW se lanzará en el primer trimestre de 2023 Uncategorized
  • Space Electronics Market to Reach $5.36 Billion, Globally, by 2031 at 5.04% CAGR: Allied Market Research Uncategorized

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Art of Living
  • Arts
  • Auto & Transportation
  • Automobile
  • Aviation
  • Banking
  • BCA ELECTIONS 2026
  • Bollywood
  • Brands
  • Business
  • Business Technology
  • Commodities
  • Economy
  • Education
  • Energy
  • Entertain­ment & Media
  • Entertainment
  • Entrepreneurs
  • Environment
  • Financial Services & Investing
  • Fitness
  • Gadgets
  • Health
  • Housing & Infrastructure
  • India
  • Information Technology
  • International
  • International Education
  • Investment
  • Lifestyle
  • Narendra Modi
  • News
  • People & Culture
  • Pharma
  • Policy & Public Interest
  • Politics
  • Sports
  • Stock Market
  • Tamilnadu
  • Technology
  • Telecom
  • The Multitaskers: A Series On Entrepreneurship with difference.
  • Travel
  • Uncategorized
  • UNICEF
  • Wellness
  • World News

Recent Posts

  • Opposition to ring the Election Commission tomorrow: Congress maps a street-to-Parliament campaign through October and November
  • Cockroach Party to CEC: Quit in 48 Hours — or We Take the Fight Nationwide Over 13 Crore Deleted Voters
  • A Temple of Health and a ₹1-Lakh-Crore Bet: Bengal CM, Gautam Adani Break Ground on 2,000-Bed Arogya Mandir
  • Baroda’s Moliya Captains Rest of India U-23 for CK Nayudu Trophy Clash in Chennai
  • Modi’s Poll Chief Faces Mutiny From His Own Bench.

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • October 2021
  • September 2021

  • How Construction ERP is Revolutionizing Project Management Brands
  • Change Of Guard At IBA: Dr. D. S. Gangwar Appointed As New Secretary General Brands
  • Mayfair Polo and Artize Join Forces to Chart a Royal Route to the Jaipur Polo Season Brands
  • HROne Launches One AI Suite – Featuring India’s First Employee AI Agent for HR Task Execution Brands
  • Reduce Your Cloud Costs by 60 Percent-No Foreign Hyperscalers, Just Bharat Ka Apna Cloud Brands
  • Match Fixing: The Nation At Stake Wins Hearts With Unique Storytelling And Stellar Direction Brands
  • Jainson Locks and Klosher Global Host Pragati 2025 in Delhi: Unveiling Innovation with New Product Launches Brands
  • Manaksia Coated Metals & Industries Reports ₹790 Cr Total Income & ₹15 Cr Net Profit in FY25 Brands

Powered by PressBook News WordPress theme